New shot could tame tough eczema Flare-Ups
NCT ID NCT07377838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests an injection called ADSTEM for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to standard treatments. About 286 people aged 19 to 70 will receive either the study drug or a placebo. The main goal is to see if the injection can clear or nearly clear the skin rash.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?